Patients who experienced out-of-hospital cardiac arrest and were shocked by a bystander were significantly more likely to survive to discharge compared with patients who were initially shocked by emergency medical services.
Implantable cardioverter defibrillator placement in patients with chronic kidney disease was associated with increased risk for heart failure-related and any-cause hospitalization.
The HeartStart MRx defibrillator may fail at any time, including during repeated shocks while in AED mode.
MRI conducted at a strength of 1.5 Tesla is safe for patients with a legacy pacemaker or implantable cardioverter-defibrillator system.
ICD therapy reduced the incidence of sudden and all-cause mortality in comparison to conventional care for ischemic or nonischemic cardiomyopathy.
Long-Detection Programming in Single-Chamber Implantable Cardioverter Defibrillators Reduces Shocks and PacingMay 17, 2017
Long-detection programming improved survival, decreased the likelihood of hospitalization, and reduced therapy in patients with single-chamber ICDs.
None of the patients had device failure during the MRI; however, 6 patients did have atrial fibrillation or flutter but each case stopped on its own.
Nearly half of all implantable cardioverter defibrillator shock events utilized health care.
Cardiac resynchronization therapy with defibrillation correlated with reduced hospitalization or all-cause mortality and all-cause mortality in advanced systolic heart failure.
Of 307 patients, only 1 patient's ICD had electromagnetic interference produced by a telephone.
In older adults who received implantable cardioverter-defibrillators as secondary prevention of sudden cardiac death, the risk of death was 21.8%.
St. Jude Medical implantable cardiac devices and the Merlin@home Transmitter may be vulnerable to cybersecurity attacks.
Researchers conducted a study to determine the risk of VT/VF using wearable cardioverter defibrillators after ICD explantation.
Complication rates were 13.7% and 18.0%, respectively, in the subcutaneous ICD and transvenous ICD groups and infection rates were 4.1% vs 3.6%.
Anticoagulation therapy may not reduce stroke risk for patients with ICDs who have only brief episodes of AT or AF.
Implantable cardioverter defibrillators and cardiac resynchronization therapy defibrillators manufactured by St. Jude Medical may have batteries that will prematurely deplete.
Cardiac recovery was independently predicted by age, nonischemic cardiomyopathy, time from cardiac diagnosis, lack of ICD, serum creatinine levels, and LV end-diastolic dimensions.
Previously abandoned leads were associated with more complications from infection.
Safety and efficacy of exercise training in patients with heart failure with implantable cardioverter defibrillators.
Of the 556 patients assigned to receive an ICD, 120 died compared with 131 in the control group who received usual care.
Updated analyses and insights from the first cardiac resynchronization therapy-heart failure mortality/morbidity trial comparing defibrillator or pacemaker with pharmacologic therapy alone.
Catheter Ablation vs Antiarrhythmic Drug Escalation Therapy in Patients With Ventricular TachycardiaMay 05, 2016
The catheter ablation group experienced a significantly lower rate of the primary outcome compared with the escalated therapy group.
Researchers analyzed the performance of 3 types of implantable cardioverter-defibrillators: single-chamber, dual-chamber, and cardiac resynchronization therapy devices.
The biventricular pacing arm showed greater improvement in New York Heart Association functional class at 12 months.
Risk of thromboembolic complications was 5 times higher among patients without therapeutic anticoagulation during cardioversion.
Two studies suggest that atrial fibrillation results in reduced physical activity among older adults.
Results indicated that the rate of patients who received bystander CPR increased at home and in public first-responder defibrillation increased at home but not in public.
Wearable cardioverter-defibrillators are reasonable bridges to more "definitive therapy" or in situations associated with increased risk of death in which implantable defibrillators reduce sudden cardiac death but not overall survival.
Few patients with implantable cardioverter defibrillators are aware that they can deactivate their devices in their final days to avoid painful shocks.
The Cardiology Advisor Articles
- FDA Reports Combination Hypertension Treatment Discontinued
- Automated Detection of Atrial Fibrillation Through Smartwatch Technology
- Cardiovascular Outcomes of SGLT-2i vs Other Glucose-Lowering Drugs in T2D
- Outcomes With Aspirin for Primary Prevention in Heart Failure, Type 2 Diabetes
- Machine Learning Shows Potential in Diagnosing Myocardial Infarction in Patients With Chest Pain
- Digital Adherence Devices: Preventing Strokes in Afib One Reminder at a Time
- Pioglitazone Lowers Cardiovascular, Noncardiovascular Mortality in Diabetes
- Peripheral Artery Disease, DVT Risk May Increase With Varicose Veins
- Cardiorespiratory Fitness May Improve Executive Function in Mild Cognitive Impairment
- Preventing Chemotherapy-Related Cardiotoxicity in Breast Cancer
- Patent Foramen Ovale Characteristics May Predict Benefits of PFO Closure
- Low-Dose Triple Combo Therapy Effective in Hypertension
- Blood Pressure, Glucose Levels Worsened From the Great Recession
- Acute MI Hospital Mortality During Transcatheter Cardiovascular Therapeutics Meeting Dates
- A 64-Year-Old Woman With Colorectal Cancer Presents to ED With Severe Chest Pain